Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Double-Blind Phase III Study of Fulvestrant 500 mg vs 250 mg in Advanced Breast Cancer
2004-002371-16Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fulvestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to progression. Started Oct 2004; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-002371-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002371-16.